Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Treatment

Link to article at PubMed

Med Clin North Am. 2023 Jul;107(4):781-792. doi: 10.1016/j.mcna.2023.03.009. Epub 2023 Apr 20.

ABSTRACT

Hepatorenal syndrome (HRS) is a primarily functional form of acute kidney injury (AKI) that develops in patients with decompensated cirrhosis. The pathophysiologic cascade that leads to HRS begins with pooling of blood in the splanchnic system, resulting in a decrease in effective circulating arterial volume. The definitive treatment of HRS is liver transplantation. When this is not possible, HRS is treated with a combination of vasoconstrictor agents and intravenous albumin. Although the combination of midodrine and octreotide is used in the United States, the recently approved terlipressin, an analog of vasopressin, is likely to become the first-line standard of care.

PMID:37258014 | DOI:10.1016/j.mcna.2023.03.009

Leave a Reply

Your email address will not be published. Required fields are marked *